Cara Therapeutics Inc. announced the appointment of Helen M. Boudreau to serve as a member of the Board effective immediately with a term expiring at the Company?s 2024 Annual Meeting of Stockholders. Ms. Boudreau was appointed to serve as a member of audit committee of the Board. Ms. Boudreau has more than 30 years of operating experience in a variety of industries, including the biotechnology and pharmaceutical sectors, in addition to serving as a director on numerous public boards.

Helen M. Boudreau, age 57, currently serves as managing director at Estuary Ventures LLC. From June 2018 to July 2019, she served as Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute. Previously, she served as Chief Financial Officer from July 2017 to June 2018 and as a member of the board of directors from February 2016 to July 2017 for Proteostasis Therapeutics, Inc. Ms. Boudreau currently serves as a board member of Premier, Inc., Shattuck Labs Inc., and Rallybio Corp, positions she has held since June 2020, July 2020 and September 2020, respectively.

Ms. Boudreau also previously served on the board of directors of Reunion Neuroscience, Inc., from April 2020 to August 2023 and Evaxion Biotech A/S, from June 2020 to May 2021. Ms. Boudreau earned a B.A. in Economics from the University of Maryland and an M.B.A. from the Darden Graduate School of Business at the University of Virginia. Ms. Boudreau is Directorship CertifiedTM by the National Association of Corporate Directors (NACD) and earned the CERT Certificate in Cybersecurity Oversight from Carnegie Mellon University Software Engineering Institute and NACD.